SAN CARLOS, Calif.-- October 14, 2026 -- Altay Therapeutics, Inc., a biotechnology company developing novel small molecule inhibitors of transcription factors, today announced the completion of a $37 million Series...


Elitra, whose assets were acquired by Merck in 2004, was an antimicrobial functional genomics company that focused on the identification, development and commercialization of novel antimicrobial compounds that target essential gene products of pathogenic organisms.
Elitra Phramaceuticals
San Diego, CA